Codrituzumab

Recurrent or Refractory Glypican 3 (GPC3)

Memorial Sloan Kettering Cancer CenterPhase 1

—

Rating in progress

Codrituzumab in Recurrent or Refractory Glypican 3 (GPC3) is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.

Methodology v0.2 · Active